Human CSF Endopeptidome Study in MS and NMOSD

In a laboratory analysis, researchers identified 381 endogenous peptides in the cerebrospinal fluid (CSF) of treatment-naïve patients with clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and neuromyelitis optica spectrum disorder (NMOSD). A specific C-terminal peptide from secretogranin-5 was notable for decreasing in abundance from CIS to RRMS. NMOSD patients showed reduced peptide levels and oxidative modifications.

Tags: #Biomarkers
Most relevant to: —
Source: Read original source (PMID 42831274)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

This research highlights the potential of the CSF endopeptidome as a tool for understanding inflammatory demyelinating disorders, revealing disease-associated peptide changes which could aid in future studies.

What this does not prove

The study is exploratory; it does not provide definitive clinical utility or validate findings across larger patient groups, limiting its applicability.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Laboratory
Participants / samples: Not reported
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-10-05
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Biomarkers, Other

Original sources

Primary evidenceTop-Down CSF Peptidomics Reveals Disease-Associated Peptide Signatures and Oxidative Modifications in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. ↗DOI: 10.1002/pmic.70188

Supporting passages (7)

study phaseThe results revealed disease-associated patterns of granin-, osteopontin-, proSAAS-, and fibrinogen-derived peptides, especially for oxidative derivatives.

study designHere, we applied a high-resolution top-down peptidomic approach in CSF from treatment naïve patients with CIS, relapsing-remitting multiple sclerosis (RRMS), NMOSD, and non-inflammatory neurological controls.

subjectsIn this top-down exploratory study, we characterized for the first time the CSF endopeptidome of treatment-naïve patients with CIS, RRMS stratified by oligoclonal-band (OCBs) status, NMOSD, and non-inflammatory neurological controls.

research categoriesThese findings support the CSF endopeptidome as a complementary molecular layer for investigating regulated proteolysis and redox-dependent alteration in inflammatory demyelinating disorders and identify peptide candidates for future validation in independent cohorts.

publication datePublication date: 2026-10-05

findingsOverall, these findings support the CSF endopeptidome as a biologically informative molecular layer associated with secretory pathway alteration, PTMs, and intrathecal inflammation.

limitationsTitle: Top-Down CSF Peptidomics Reveals Disease-Associated Peptide Signatures and Oxidative Modifications in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.